Expression of SATB2 in gastrointestinal adenocarcinoma and its diagnostic value

CHENG Kai; HE Yan; ZHANG Ru-song; SHI Qun-li

doi:10.3969/j.issn.1007-8096.2018.02.003

Abstract：Objective To detect the expression of SATB2 in gastrointestinal adenocarcinoma and its diagnostic value.Methods The expression of SATB2,CDX-2 and CDH17 was detected using immunohistochemical EnVision two-step method in 92 cases of colorectal carcinoma and 69 cases of gastric carcinoma.Results The positive rates of SATB2,CDX-2 and CDH17 in colorectal carcinoma were 81.5％～ 82.6％,94.6％ and 96.7％;the positive rates of SATB2,CDX-2 and CDH17 gastric carcinoma were 8.7％～ 10.1％,59.4％ and 78.2％,respectively;the expression of all three markers showed significance difference between colorectal carcinoma and gastric carcinoma (P ＜ 0.05).The positive predictive value of SATB2,CDX-2 and CDH17 in the differencial diagnosis of colorectal carcinoma and gastric carcinoma was 81.5％-82.6％,94.6％ and 96.7％,respectively;the negtive predictive value was 89.9％-91.3％,40.6％ and 21.7％,respectively.All of the three anti-SATB2 antibody showed nuclear immunoreactivity,the repeatabilites of positive rate and staining intensity were better among all the three anti-SATB2 monoclonal antibodies (κ =0.93).Conclusion The expression of SATB2 in colorectal carcinoma is significantly high than that in gastric carcinoma,which is prior to CDX-2 and CDH17 in the differencial diagnosis of colorectal carcinoma and gastric carcinoma.